Drug-Resistant Tuberculosis Treatment Outcomes
Summary
Drug-resistant tuberculosis represents a major obstacle to global TB control, with outcomes that consistently fall short of WHO targets. Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) account for the majority of treatment failures and deaths, driven by complex resistance patterns, delayed diagnosis and social determinants such as malnutrition, comorbidity and unstable access to care. Overall success rates for MDR-TB range between 50 and 60 %, while XDR-TB treatment success remains below 50 %. Common predictors of poor outcome include HIV coinfection, low body mass index, advanced age, psychiatric illness and alcohol misuse. Recent advances in molecular diagnostics and novel pharmacological agents—such as direct InhA inhibitors—offer hope for shortening regimens and overcoming specific resistance mechanisms. Nutritional support and close monitoring of surrogate markers, notably weight gain and sputum culture conversion, have emerged as practical tools to guide individualised therapy in resource-limited settings.
Research from Nature Portfolio
Recent studies in resource-limited settings have highlighted the prognostic value of monitoring body weight during MDR-TB treatment. In a large retrospective cohort in northwest Ethiopia, serial weight gain over the course of therapy was inversely associated with unsuccessful outcomes, while undernutrition, HIV coinfection and complications such as pneumothorax increased hazard of treatment failure. These findings support the use of weight trajectories as a simple surrogate marker for treatment response and underline the importance of integrated nutritional and clinical care in improving MDR-TB outcomes.
Drug-Resistant Tuberculosis Treatment Outcomes publication trend
The graph below shows the total number of articles in drug-resistant tuberculosis treatment outcomes across all publications each year (not limited to Nature Index journals).
Technical terms
Multidrug-resistant tuberculosis (MDR-TB): Disease caused by Mycobacterium tuberculosis strains resistant to at least isoniazid and rifampicin.
Extensively drug-resistant tuberculosis (XDR-TB): MDR-TB plus resistance to any fluoroquinolone and at least one second-line injectable agent.
Sputum culture conversion: Transition from positive to negative Mycobacterium tuberculosis cultures in respiratory specimens, indicating microbiological response.
Surrogate marker: A measurable clinical or laboratory parameter used to infer overall treatment efficacy.
Treatment success: Completion of therapy with bacteriological cure, as defined by WHO outcome categories.
References
- Treatment outcomes and risk factors for an unsuccessful outcome among patients with highly drug-resistant tuberculosis in Ukraine. Clinical Microbiology and Infection (2023).
- Global treatment outcomes of extensively drug-resistant tuberculosis in adults: A systematic review and meta-analysis. Journal of Infection (2023).
- Proteomics study the potential targets for Rifampicin-resistant spinal tuberculosis. Frontiers in Pharmacology (2024).
- Incidence, Outcomes, and Risk Factors for Isoniazid-Resistant Tuberculosis from 2012 to 2022 in Eastern China. Antibiotics (2024).
- Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. Antimicrobial Agents and Chemotherapy (2024).
- Impacts of body weight change on treatment outcomes in patients with multidrug-resistant tuberculosis in Northwest Ethiopia. Scientific Reports (2024).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.